Eric Cantor, the former House majority leader known for his role as the GOP's chief political strategist, is now tasked with guiding the pharmaceutical industry through Washington's turbulent politics. According to STAT, Cantor's new position at PhRMA comes at a time when drug pricing and industry influence are under intense scrutiny from both parties.
Cantor has navigated similar terrain before. In 2013, he gathered with Republican colleagues at a Virginia resort to push the party away from its reputation as a defender of the rich and corporate interests, as detailed in a New Yorker profile. That effort was aimed at addressing growing populist currents within the electorate.
Now, the question is whether those old political instincts can translate to the pharmaceutical lobby. The industry faces pressure from the Trump administration and a broader populist mood that is skeptical of corporate power. Cantor's history suggests he understands the need to rebrand, but whether he can reconcile pharma's interests with public demands for lower drug prices remains an open question, according to the STAT analysis.